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ABSTRACT 
Over the past three decades, there has been a considerable research interest in the area of developing drug delivery using nanoparticles (NPs) as 
carriers for small and large molecules. Targeting delivery of drugs to the diseased lesions is one of the most important aspects of drug delivery 
system. They have been used in vivo to protect the drug entity in the systemic circulation, restrict access of the drug to the chosen sites and to 
deliver the drug at a controlled and sustained rate to the site of action. Various polymers have been used in the formulation of nanoparticles for 
drug delivery research to increase therapeutic benefit, while minimizing side effects. In order to see functionality and toxicity of nanoparticles in 
various food and drug applications, it is important to establish procedures to prepare nanoparticles of a controlled size. NaturalControlled release of 
drugs from nanostructured functional materials, especially nanoparticles (NPs), is attracting increasing attention because of the opportunities in 
cancer therapy and the treatment of other ailments. The potential of magnetic NPs stems from the intrinsic properties of their magnetic cores 
combined with their drug loading capability and the biochemical properties that can be best owed on them by means of a suitable coating. This  
review was mainly focused on different techniques for the preparation of magnetic nanoparticles and their application in various field. In addition 
to that some of the applications in the field of biomedicine were also explained. 
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INTRODUCTION 
Nanotechnology is beginning to allow scientists, engineers, and 
physicians to work at the cellular and molecular levels to produce 
major advances in the life sciences and healthcare. Magnetic 
nanoparticles show remarkable new phenomena such as 
superparamagnetism, high field irreversibility, high saturation field, 
extra anisotropy contributions or shifted loops after field cooling. 
These phenomena arise from finite size and surface effects that 
dominate the magnetic behaviour of individual nanoparticles.1,2 
Advantages 
The main advantages of magnetic (organic or inorganic) NPs are that 
they can be: (i) visualized (superparamagnetic NPs are used in MRI); 
(ii) guided or held in place by means of a magnetic field; and (iii) 
heated in a magnetic field to trigger drug release or to produce 
hyperthermia/ablation of tissue.  
The other advantages of magnetic nanoparticles drug delivery 
sytems include  (i) the ability to target specific locations in the body; 
(ii) the reduction of the quantity of drug needed to attain a 
particular concentration  in the vicinity of the target; and (iii) the 
reduction of the concentration of the drug at non target sites 
minimizing severe side effects.  
Different methods for the preparation of magnetic 
nanoparticles1 
several popular methods including co-precipitation, microemulsion, 
thermal decomposition, solvothermal ,  chemical vapour deposition, 
combustion synthesis, carbon arc, laser pyrolysis synthesis have 
been reported for synthesis of MNPs. 
LIQUID PHASE SYNTHSIS 
The principles by which monodisperse (with a relative standard 
deviation of ~ 5%) particles can be prepared are readily presented 
in a diagram due to LaMer . As described in the LaMer diagram for 
homogeneous precipitation, as concentration  increases to pass its 
saturation, it reaches a point where nucleation occurs. Particle  
 
growth most likely transpires by a combination of the diffusion of 
atoms onto the nuclei and with irreversible aggregation of nuclei. 
The requirements for  monodispersity are evident from  the LaMer 
diagram: 
 
Figure 1 LaMer diagram 
The rate of nucleation must be high enough so that the concentration 
does not continue to climb. Instead, a burst of nuclei are created in a 
short period (τ short). 
The rate of growth of these nucleis must be fast enough to reduce 
the   concentration below  the nucleation concentration point, 
quickly. In this way only a limited number of particles are created. 
The rate of growth must be slow enough, however, that the growth 
period is long  compared with the nucleation period. 
This usually narrows the size of distribution which results from 
finite nucleation period. So, by controlling these factors 
monodisperse MNPs with different sizes can be synthesized. 
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Co-precipitation is a facile and convenient way to synthesize MNPs 
(metal oxides and ferrites) from aqueous salt solutions. There are 
two main methods for the synthesis in solution of magnetite 
spherical particles in the nanometre range. In the first, ferrous 
hydroxide suspensions are partially oxidized with different oxidizing 
agents . For example, 
spherical magnetite particles of narrow size distribution with mean 
diameters between 30 and 100 nm can be obtained from a Fe(II) 
salt, a base and a mild oxidant (nitrate ions). The other method 
consists in ageing stoichiometric mixtures of ferrous and ferric 
hydroxides in aqueous media, yielding spherical magnetite particles 
homogeneous in size. In addition, it has been shown that by 
adjusting the pH and the ionic strength of the precipitation medium, 
it is possible to control the mean size of the particles over one order 
of magnitude (from 15 to 2 nm) .The size decreases as the pH and 
the ionic strength in the medium increases . Both 
parameters affect the chemical composition of the surface and 
consequently, the electrostatic surface charge of the particles. Under 
these conditions, magnetite particles are formed by 
aggregation of primary particles formed within an Fe(OH)2 gel. This 
is an ordered aggregation that gives rise to spherical  crystalline 
particles .The smallest particles can also be generated after adding 
polyvinylalcohol (PVA) to the iron salts. 
Microemulsion 
The water-in-oil (W/O) microemulsion, has been widely used to 
synthesize uniform sized MNPs .This is an isotropic and 
thermodynamically stable single-phase system  that consists of three 
components: water, oil and an amphiphilic molecule, called 
surfactant. The surfactant molecule lowers the interfacial tension 
between water and oil resulting in the formation of a transparent 
solution. The water nanodroplets containing reagents, as a 
nanoreactor, undergo rapid coalescence allowing for a mixing, 
precipitation reaction and an aggregation processes for the 
synthesis of MNPs. The shape of the water pool is spherical and the 
surfactant molecules surround the nanodroplet wall. These walls act 
as cages for the growing particles and thereby reduce the average 
size of the particles during the collision and aggregation process. 
Thus, the size of the spherical nanoparticles can be  controlled and 
tuned by changing the size of the water pool (W0 value, the water-
to-surfactant molar ratio). Generally, the higher values of W0, give 
the larger particle size. By mixing two identical water-in-oil 
microemulsions containing the desired reactants, the microdroplets 
will continuously collide,coalesce and break again, and finally a 
precipitate forms in the micelles.  
Thermal Decomposition9 
Nanoparticles with a high level of monodispersity and size  control 
can be obtained by high-temperature decomposition of 
organometallic precursors, such as [Mn+(acac)n], (M = Fe, Mn, Co, 
Ni, Cr; n = 2 or 3, acac = acetylacetonate), Mx(cup)x (cup = N 
nitrosophenylhydroxylamine) or carbolys (such as Fe(CO)5) using 
organic solvents and surfactants such as fatty acids, oleic acid and 
hexadecylamine. Thermal decomposition 
of organometallic precursors which metal is the zero valent in their 
composition (such as Fe(CO)5) initially leads to a formation of metal 
NPs but if followed by oxidation can lead 
to a high in quality mono dispersed  metal oxides. On the other hand, 
decomposition of precursors with cationic metal centers (such as Fe 
(acac)3) leads directly to metal oxides NPs. Principally the ratios of 
the starting reagents including organometallic compounds, 
surfactants, and solvents are the decisive parameters for controlling 
the size and morphology of MNPs. The reaction temperature and 
time, as well as the aging period may also be crucial for the precise 
control of size and morphology.The effect of reaction temperatures 
and 
reaction times on size, morphology and magnetic properties of 
nanoparticles are schematically shown in the following figure. Metal 
oxide MNPs can also be synthesized by the thermal decomposition 
method. Up to date, two different approaches have been used for this 
purpose. First, thermal decomposition of metal carbonyl precursors 
followed by an oxidation step using air , or oxidation by using an 
oxidant at elevated temperatures .The second is decomposition of 
precursors with a cationic metal centre in the absence of reducing 
agents. The presences of reducing agents lead to metal NPs even by 
the use of cationic precursors .Thermal decomposition seems the 




Effect of reaction temperature and reaction time on size, 
morphology and magnetic properties of MNPs of production is high 
and scalable. However, one of the major disadvantages of this 
method is the production of organic soluble NPs which limit the 
extent of application  uses of them in biological fields besides surface 
treatment is needed after synthesis; also, thermal decomposition  
methods usually lead to complicated  processes or require relatively 
high temperatures. 
Chemical Reduction 
Among the various solution-phase chemistry routes developed for 
the preparation of metal NPs, the reduction of metal salts is the most 
common, and reducing agents such as NaBH4 have been commonly 
employed in the reactions. Nanoscale zero-valent iron (nZVI) which 
have been extensively used in the environmental remediation field, 
have commonly been prepared by mixing equal volumes of NaBH4 
and FeCl3, the following reaction of: 
4Fe3+ + 3NaBH4 + 9H2O → 4Fe0 ↓ + 3NaH2BO3 + 12H+ 6H2 (5) 
A key advantage of this method is its simplicity. It can be safely done 
in most chemistry labs with simple chemical reagents. Also, this 
reaction can be done at room temperature conditions. 
Applications of Magnetic nanoparticles8 
Industrial applications of magnetic nanoparticles cover a broad 
spectrum such as magnetic seals in motors, magnetic inks for bank 
cheques, magnetic recording media and biomedical applications 
such as magnetic resonance contrast media and therapeutic agents 
in cancer treatment. Each potential application requires the 
magnetic nanoparticles to have different properties. For example, in 
data storage applications, the particles need to have a stable, 
switchable magnetic state to represent bits of information, a state 
that is not affected by temperature fluctuations. For biomedical 
applications the use of particles that present superparamagnetic 
behaviour at room temperature is preferred. Furthermore, 
applications in biology and medical diagnosis and therapy require 
the magnetic particles to be stable in water at neutral pH and 
physiological salinity. The colloidal stability of this fluid will depend 
first, on the dimensions of the particles, which should be sufficiently 
small so that precipitation due to gravitation forces can be avoided, 
and second on the charge and surface chemistry, which give rise to 
both, steric and coulombic repulsions4. Additional restrictions to the 
possible particles that could be used for biomedical applications 
strongly depend on whether these particles are going to be used for 
in vivo or in vitro applications. For in vivo applications the magnetic 
particles must be coated with a biocompatible polymer during or 
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after the synthesis process to prevent the formation of large 
aggregates, changes from the original structure and biodegradation 
when exposed to the biological system. The polymer will also allow 
binding of drugs by covalent attachment, adsorption or entrapment 
on the particles .The important factors, which determine the 
biocompatibility and toxicity of these materials, are the nature of the 
magnetically responsive component, such as magnetite, iron, nickel, 
cobalt, neodimium–iron–boron or samarium–cobalt and the final 
size of the particles, their core and the coatings. Iron oxide particles 
such as magnetite (Fe3O4) or its oxidized form maghemite (γ -
Fe2O3) are by far the most commonly employed for biomedical 
applications. Highly magnetic materials such as cobalt and nickel are 
toxic, susceptible to oxidation and hence are of little 
interest.Moreover, the main advantage of using particles of sizes 
smaller than 100 nm (so-called nanoparticles) is their higher 
effective surface areas (easier attachment of ligands), lower 
sedimentation rates (high stability) and improved tissular diffusion 
.Another advantage of using nanoparticles is that the magnetic 
dipole–dipole interactions are significantly reduced because they 
scale as r6 (r is the particle radius) .Therefore, for in vivo biomedical 
applications, magnetic nanoparticles must be made of a non-toxic 
and non-immunogenic material, with particle sizes small enough to 
remain in the circulation after injection and to pass through the 
capillary systems of organs and tissues avoiding vessel embolism. 
They must also have a high magnetization so that their movement in 
the blood can be controlled with a magnetic field and so that they 
can be immobilized close to the targeted pathologic tissues 
 
Figure 3 NP system for drug delivery applications 
 
Drug delivery with magnetic NPs13,14 
Different organic materials (polymeric NPs, liposomes, micelles) 
have been investigated as drug delivery nanovectors using passive 
targeting, active targeting with a recognition moiety (e.g. antibody), 
or active targeting by a physical stimulus (e.g. magnetism in 
magnetoliposomes). However, these organic systems still present 
limited chemical and 
mechanic stability, swelling, susceptibility to microbiological attack, 
inadequate control over the drug release rate, and high cost. 
Polymer NPs also suffer from the problem of high polydispersity. 
Synthesis produces particles with a broad size distribution and 
irregular 
branching, which could lead to heterogeneous pharmacological 
properties. One alternative is to use dendrimers, which have a 
monodisperse character and globular architecture resulting from 
their stepwise synthesis and can be purified at each step of growth. 
Visualization of dendrimers requires tagging with a specific moiety 
(i.e. a fluorophore or metal). A major drawback of dendrimers and 
dendritic polymers, however, is their high cost. The preparation 
of dendritic polymers that circulate in the blood long enough to 
accumulate at target sites but that can also be removed from the 
body at a reasonable rate to avoid long-term accumulation also 
remains a challenge. Passive targeting using drug-conjugated 
dendrimers and dendritic 
polymers has been widely studied, mainly using the EPR effect. 
Therapies based on active targeting, such as antibody-conjugated 
dendrimers, constitute a promising alternative in view of the 
potential of antibodies for selective targeting. Because of the 
disadvantages of organic NPs for drug delivery, inorganic vectors 
constitute an interesting option and are the subject of intense 
research15.  
We refer to NPs when the drug is covalently attached to the surface 
or entrapped or adsorbed within the pores of the magnetic carrier 
(polymer, mesoporous silica, etc.). Nanocapsules (‘reservoirs’) 
designate magnetic vesicular systems where the drug is confined to 
an aqueous or oily cavity, usually prepared by the reverse micelle 
procedure, and surrounded by an organic membrane 
(magnetoliposomes) or encapsulated within a hollow inorganic 
capsule. The key parameters in the behavior of magnetic NPs are 
related to surface chemistry, size (magnetic core, hydrodynamic 
volume, and size distribution), and magnetic properties (magnetic 
moment, remanence, coercivity). The surface chemistry is especially 
important to avoid the action of the reticuloendothelial system 
(RES), which is part of the immune system, and increase the half-life 
in the blood stream. Coating the NPs with a neutral and hydrophilic 
compound increases the circulatory half-life from minutes to hours 
or days. Another possibility is to reduce the particle size; however, 
despite all efforts, complete evasion of the RES does not seem 
feasible and unwanted migration to other areas in the body could 
cause toxicological problems5,6. In addition to cancer treatment, 
magnetic NPs can also be used in anaemic chronic kidney disease 
and disorders associated with the musculoskeletal system (i.e. local 
inflammatory processes, side effects). For those disorders, 
superparamagnetic Fe oxide NPs (SPION), in conjunction with 
external magnetic fields, seem a suitable alternative for drug 
delivery to inflammatory sites by maintaining appropriate local 
concentrations while reducing overall dosage and side effects16. 
A list of some other applications of nanomaterials to biology or 
medicine is given below:10,17 
  Fluorescent biological labels  
  Drug and gene delivery 
  Bio detection of pathogens  
  Detection of proteins  
  Probing of DNA structure  
  Tissue engineering  
  Tumour destruction via heating (hyperthermia) 
  Separation and purification of biological molecules  
  andcells  
  MRI contrast enhancement  
Limitations of magnetic drug delivery12 
Since the magnetic gradient decreases with the distance to the 
target, the main limitation of magnetic drug delivery relates to the 
strength of the external field that can be applied to obtain the 
necessary magnetic gradient to control the residence time of NPs in 
the desired 
area or which triggers the drug desorption. Permanent Nd-Fe-B 
magnets in combination with SPION, which have excellent magnetic 
properties, can reach effective magnetic field depths up to 10-15 cm 
in the body. However, it must be noted that the magnetic carriers 
accumulate not only at the desired site but also throughout the cross 
section from the external source to the depth marking the effective 
field limit. Obviously, the geometry of the magnetic field is extremely 
important and must be taken into account when designing a 
magnetic targeting process. As a means to elude the limitations of 
using external magnetic fields, internal magnets can be located in the 
vicinity of the target by using minimally invasive surgery. Several 
studies have simulated  the interaction between a magnetic implant 
and magnetic NPs, enabling drug delivery. In addition, work in 
several laboratories is addressing targeted drug delivery with 
magnetic implants. Another limitation relates to the small size of 
NPs, a requisite for superparamagnetism, which is in turn needed to 
avoid magnetic agglomeration once the magnetic field is removed. A 
small size implies a magnetic response of reduced strength, making 
it difficult to direct particles and keep them in the proximity of the 
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target while withstanding the drag of blood flow. Targeting is likely 
to be more effective in regions of slower blood velocity, and 
particularly when the magnetic field source is close to the target site. 
As for all biomedical applications, limitations also arise in 
extrapolating from animal models to humans. There are many 
physiological parameters to consider, ranging from differences in 
weight, blood volume, cardiac output, and circulation time to tumor 
volume/location/blood flow, complicating the extrapolation of data 
obtained in animal models. Related to this point is the fact that 
studies on toxicity and the fate of magnetic carriers are insufficient 
and, in many cases, there is insufficient characterization. Finally, 
state-of-the-art magnetic drug delivery seems mainly applicable to 
well-defined tumors, as treatment of metastatic neoplasms and 
small tumors in the early stages of their growth still remains a 
challenge. Treating emerging tumors will involve the development of 
a new generation of seek-and-destroy NPs, which specifically 
recognize small clusters of cancer cells and carry the necessary 
elements (drugs or hyperthermia agents) for their destruction. A 
strong interest continues in this field given the capability of NPs to 
access tumors in regions where conventional surgery cannot be 
applied. 
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